Foghorn Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Foghorn Therapeutics R&D Spending Growth & History (FHTX)
Foghorn Therapeutics's r&d spending was $85.5M for fiscal 2025.
View full Foghorn Therapeutics company overviewFoghorn Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $85.5M | −$9.1M | −9.59% |
| 2024 | 2024-12-31 | $94.5M | −$15.2M | −13.82% |
| 2023 | 2023-12-31 | $109.7M | $4.1M | +3.85% |
| 2022 | 2022-12-31 | $105.6M | $25.3M | +31.49% |
| 2021 | 2021-12-31 | $80.3M | $22.6M | +39.18% |
| 2020 | 2020-12-31 | $57.7M | $13.4M | +30.10% |
| 2019 | 2019-12-31 | $44.4M | — | — |
Foghorn Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.5M | −$3.3M | −15.00% |
| Q1 2026 | 2026-03-31 | $18.3M | −$3.4M | −15.57% |
| Q4 2025 | 2025-12-31 | $22.0M | $1.5M | +7.50% |
| Q3 2025 | 2025-09-30 | $20.0M | −$4.7M | −18.98% |
| Q2 2025 | 2025-06-30 | $21.8M | −$2.0M | −8.43% |
| Q1 2025 | 2025-03-31 | $21.6M | −$3.9M | −15.31% |
| Q4 2024 | 2024-12-31 | $20.5M | −$3.7M | −15.27% |
| Q3 2024 | 2024-09-30 | $24.7M | −$1.6M | −5.95% |
| Q2 2024 | 2024-06-30 | $23.8M | −$5.5M | −18.64% |
| Q1 2024 | 2024-03-31 | $25.5M | −$4.5M | −14.84% |
| Q4 2023 | 2023-12-31 | $24.2M | −$4.0M | −14.19% |
| Q3 2023 | 2023-09-30 | $26.3M | −$677,000 | −2.51% |
| Q2 2023 | 2023-06-30 | $29.2M | $3.3M | +12.60% |
| Q1 2023 | 2023-03-31 | $30.0M | $5.5M | +22.35% |
| Q4 2022 | 2022-12-31 | $28.2M | $5.7M | +25.58% |
| Q3 2022 | 2022-09-30 | $26.9M | $6.4M | +31.39% |
| Q2 2022 | 2022-06-30 | $26.0M | $7.3M | +39.33% |
| Q1 2022 | 2022-03-31 | $24.5M | $5.8M | +30.88% |
| Q4 2021 | 2021-12-31 | $22.5M | $6.0M | +36.38% |
| Q3 2021 | 2021-09-30 | $20.5M | $4.4M | +27.19% |
| Q2 2021 | 2021-06-30 | $18.6M | $5.0M | +36.79% |
| Q1 2021 | 2021-03-31 | $18.7M | $7.2M | +62.79% |
| Q4 2020 | 2020-12-31 | $16.5M | — | — |
| Q3 2020 | 2020-09-30 | $16.1M | $4.8M | +42.69% |
| Q2 2020 | 2020-06-30 | $13.6M | — | — |
| Q1 2020 | 2020-03-31 | $11.5M | — | — |
| Q3 2019 | 2019-09-30 | $11.3M | — | — |
Foghorn Therapeutics r&d spending trends
Over the last five fiscal years, Foghorn Therapeutics's r&d spending increased from $57.7M to $85.5M, a change of $27.8M. The latest reported quarter, Q2 2026, shows $18.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Foghorn Therapeutics source filings ↗